A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1150 participants.

Also called NCT05171049

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,150 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05171049
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Austria, Canada, China, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Latvia, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05171049. Randomized; single masking; primary purpose treatment. Start 2022-05-05 (actual); primary completion 2026-02-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
Acronym
ASTER
Condition
Venous Thromboembolism
Condition
Deep Venous Thrombosis
Intervention (Biological)
Abelacimab
Intervention (Drug)
Apixaban
Lead sponsor
Anthos Therapeutics, Inc. (class: industry)
Collaborator
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05171049
Content hash
736283419e02e467e8a6bb3e44ca0cc2ddf9678fd0412fafc0d0e65f532fdaa5